Where I see patients (4)
My reviews
Selected research
-
Pre- or post-chemotherapy: effect on PSMA uptake.
EJNMMI research
-
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025.
Journal of the National Comprehensive Cancer Network : JNCCN
-
Racial variation in the advanced prostate cancer genome.
Prostate cancer and prostatic diseases
Clinical trials
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
rPFS is defined as the amount of time from the initiation of study therapy and the day of first documented radiographic disease progression per RECIST version 1.1 and PCWG3 criteria. The proportion of patients without radiographic...
Recruiting
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastati...
To compare the PFS between treatment arms. PFS is defined as the time (month) interval between date of randomization and date of radiographic disease progression or death for those without prior evidence of progression, as assesse...
Recruiting
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant ...
Defined as either objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (complete response (CR), partial response (PR)) or confirmed >= 50% decline from serum prostate-specific antigen (PSA) at ...
Recruiting
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With So...
On overall response will be reported as a percentage of participants with a complete response (CR) or partial response (PR) as measured by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Recruiting
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the...
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment...
Recruiting
4.9